Teva Pharma (TEVA) – StreetInsider.com Reports
-
Teva Pharma (TEVA) and Teva (TEVA) Announce FDA Approval of SELARSDI
-
Teva Pharma (TEVA) Reports Phase 3 Results Confirming Efficacy and Safety of AJOVY
-
Teva Pharma (TEVA) and mAbxience Announce Strategic Global Licensing Agreement for Oncology Biosimilar Candidate
-
UroGen Pharma (URGN) Files Patent Infringement Action Against Teva Pharmaceuticals (TEVA)
-
Teva Pharma (TEVA) PT Raised to $17 at Jefferies, 'Innovation Strategy Resonating'
-
JPMorgan Upgrades Teva Pharma (TEVA) to Neutral, 'we remain cautious'
-
Teva Pharma (TEVA) and Jiangsu Nhwa Forge Strategic Partnership to Promote Patient Access to AUSTEDO in China
-
Alvotech (ALVO) and Teva (TEVA) Announce US Approval of SIMLANDI
-
Increasing unusual option volume: BTAI MAT LSCC NYCB FOXA LXRX FROG HEAR WISH TEVA
-
Teva Pharma (TEVA) February and June spreader active
-
Midday movers: Diamondback Energy rises, Arm goes parabolic
-
Piper Sandler Upgrades Teva Pharma (TEVA) to Overweight, 'The Times They Are A-Changin’'
-
4 small and mid-cap biopharma stocks to own according to BofA
-
Teva Pharma (TEVA) PT Raised to $11 at Goldman Sachs
-
Teva Pharma (TEVA) Mentioned Positively at Oppenheimer
-
Teva Pharma (TEVA) PT Raised to $17 at Barclays
-
Teva Pharma sees lower 2024 profit but higher sales after large Q4 beat
-
Teva Pharma (TEVA) Tops Q4 EPS by 23c, offers outlook
-
Teva Pharma (TEVA) to Divest API Business
-
Teva Pharma (TEVA) February 12 calls active into quarter results and outlook
-
Teva Pharma (TEVA) February weekly 12 straddle into quarter results
-
Teva Pharma (TEVA) PT Raised to $15 at Barclays
-
Teva Pharma (TEVA) PT Raised to $11 at JPMorgan
-
Jefferies Upgrades Teva Pharma (TEVA) to Buy, 'Expect Trends to Drive Better Guide + Biosim Call Options'
-
Teva Pharma (TEVA) PT Raised to $14 at BofA Securities following US generics segment review
-
Piper Sandler Upgrades Teva Pharma (TEVA) to Neutral
-
Corcept loses patent spat against Teva, shares tumble
-
Corcept Therapeutics (CORT) Sinks After Court Rules for Teva (TEVA) in Patent Case
-
UnitedHealth and AbbVie 2 of several pharma names cut at HSBC
-
HSBC Starts Teva Pharma (TEVA) at Buy, 'innovative medicine division to become a driver of growth'
-
Teva Pharma (TEVA) and Biolojic Design Announce Exclusive License Agreement for the Development of a Therapeutic Antibody for Atopic Dermatitis and Asthma
-
Midday movers: Affirm, Amazon, and More
-
Teva Pharma 'uniquely positioned,' Jazz Pharmaceuticals set-up balanced - UBS
-
UBS Upgrades Teva Pharma (TEVA) to Buy, 'Everything deserves a fresh start'
-
Teva Pharma (TEVA) Announces US Approval of a Generic Version of Forteo
-
BofA more confident in Teva Pharma (TEVA) after management meetings
-
Royalty Pharma (RPRX) and Teva (TEVA) Collaborate to Further Accelerate Olanzapine Lai Program
-
Teva Pharma (TEVA) and Royalty Pharma (RPRX) Collaborate to Further Accelerate Olanzapine LAI Program
-
Teva says Israel-Hamas war not hurting production, eyes growth in 2024
-
Teva Pharma (TEVA) Reports In-Line Q3 EPS, Beats on Revenue; Offers FY23 Guidance
-
Teva Pharma (TEVA) Appoints R. Ananthanarayanan as CEO of Teva Active Pharmaceutical Ingredients
-
Teva Pharma (TEVA) November weekly 9 straddle is priced into quarter results
-
VistaGen Therapeutics (VTGN) Appoints Joshua Prince as COO
-
Teva Pharma (TEVA) Reports Phase IV UNITE Study Shows AJOVY Reduced Migraine Attacks and Depression Symptoms
-
Teva Pharma (TEVA) call put ratio 1 call to 2.1 puts as share price down 3.2%
-
Israel-based stocks fall amid Hamas attacks
-
Teva Pharma (TEVA) 30-day option implied volatility
-
Teva Pharma (TEVA) and Sanofi (SNY) Enter Exclusive Collaboration to Deliver Inflammatory Bowel Disease Treatment
-
These 10 stocks are BofA's top ideas for Q4
-
Teva Pharma (TEVA) Announces Executive Changes
Back to TEVA Stock Lookup